thalidomide has been researched along with Leprosy, Borderline in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leprosy, Borderline: A form of LEPROSY in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one of these two polar or principal forms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment." | 5.08 | IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. ( Estrada-Garcia, I; Estrada-Parra, S; Favila-Castillo, L; Gomez-Melgar, M; Partida-Sanchez, S; Pedraza-Sanchez, S; Saul, A, 1998) |
| "Thalidomide treatment is extremely effective at ameliorating ENL symptoms." | 1.43 | Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum. ( Amadeu, TP; Barbosa, MG; Brandão, SS; Costa, Fda M; Dos Santos, JB; Ferreira, H; Hacker, Mde A; Machado, Ade M; Mendes, MA; Nery, JA; Pacheco, Fdos S; Pinheiro, RO; Prata, RB; Rodrigues, LS; Sales, AM; Sarno, EN; Schmitz, V, 2016) |
| "Thalidomide therapy was required to treat the systemic manifestations of ENL." | 1.28 | Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. ( Kaplan, G; Malta, AM; Moreira, AL; Sampaio, EP; Sarno, EN, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Verma, R | 1 |
| Vasudevan, B | 1 |
| Pragasam, V | 1 |
| Moorchung, N | 1 |
| Mitra, D | 1 |
| Gopal, M | 1 |
| Schmitz, V | 1 |
| Prata, RB | 1 |
| Barbosa, MG | 1 |
| Mendes, MA | 1 |
| Brandão, SS | 1 |
| Amadeu, TP | 1 |
| Rodrigues, LS | 1 |
| Ferreira, H | 1 |
| Costa, Fda M | 1 |
| Dos Santos, JB | 1 |
| Pacheco, Fdos S | 1 |
| Machado, Ade M | 1 |
| Nery, JA | 1 |
| Hacker, Mde A | 1 |
| Sales, AM | 1 |
| Pinheiro, RO | 1 |
| Sarno, EN | 3 |
| Sampaio, EP | 2 |
| Malta, AM | 2 |
| Kaplan, G | 2 |
| Partida-Sanchez, S | 1 |
| Favila-Castillo, L | 1 |
| Pedraza-Sanchez, S | 1 |
| Gomez-Melgar, M | 1 |
| Saul, A | 1 |
| Estrada-Parra, S | 1 |
| Estrada-Garcia, I | 1 |
| Moreira, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Leprosy, Borderline
| Article | Year |
|---|---|
Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Topics: Clofazimine; Dapsone; Drug Therapy, Combination; Erythema Nodosum; Humans; Interferon-gamma; Leprost | 1996 |
IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Topics: Adolescent; Adult; Aged; Antibodies, Bacterial; Data Interpretation, Statistical; Erythema Nodosum; | 1998 |
3 other studies available for thalidomide and Leprosy, Borderline
| Article | Year |
|---|---|
Bullous erythema nodosum leprosum manifesting in the post partum period with unusual features.
Topics: Adult; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromato | 2015 |
Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
Topics: Adolescent; Adult; Aged; Biopsy; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Bord | 2016 |
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients.
Topics: Erythema Nodosum; Humans; Interferon-gamma; Leprosy, Borderline; Leprosy, Lepromatous; Monocytes; Re | 1992 |